ERBB2 and breast carcinoma: Researchers have found that autophagy promotes resistance to lapatinib, a HER2/EGFR tyrosine kinase inhibitor, in HER2-positive breast cancer (166) as well as the anti-HER2 monoclonal antibody trastuzumab (167).